Your browser does not support JavaScript or it may be disabled!
rediff.com
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
NEWS ON MOBILE
Get Realtime News
on your webpage

About 798 results for "Ibrutinib"

[Articles] Ibrutinib combined with bendamustine and rituximab ...

To view the full text, please login as a subscribed user or purchase a subscription . Click here to view the full text on ScienceDirect. Figure 1 Patient flow and disposition *All randomised patients were analysed as an ... Lancet Neurology, 5 days ago

4 images for Ibrutinib

OncLive, 3 weeks ago
Cancer Therapy Advisor, 3 weeks ago
ASH Clinical News, 3 weeks ago
ASH Clinical News, 3 weeks ago
Cancer Therapy Advisor

[Comment] Ibrutinib in chronic lymphocytic leukaemia: alone or in combination?

The current gold standard for most patients with chronic lymphocytic leukaemia is chemoimmunotherapy with anti-CD20 monoclonal antibodies and cytotoxic drugs. 1 The combination of bendamustine with rituximab is commonly used in patients with ...
 Lancet Neurology5 days ago Adding Ibrutinib to R-Bendamustine Improves Outcomes in R/R CLL/SLL  Cancer Therapy Advisor1 month ago ASH: Ibrutinib Bests Chlorambucil in Chronic Lymphocytic Leukemia  Doctors Lounge2 months ago Pediatric-like Leukemia Treatment May Be Effective for Lymphoblastic Lymphoma  Cancer Therapy Advisor1 month ago

Clinical Trial: A Drug Interaction Study to Assess the Effect of Omeprazole on the Pharmacokinetics of Ibrutinib in Healthy Adults

The article below represents a preview only and is not meant for reuse or republishing. U.S., Dec. 28 -- ClinicalTrials.gov registry received information related to the study (NCT02638116) titled 'A Drug Interaction Study to Assess the Effect of ...
 HT Syndication1 month ago

Opinion/decision on a Paediatric investigation plan (PIP): Imbruvica, Ibrutinib, Therapeutic area: Oncology

European Medicines Agency - Science, medicines, health An agency of the European Union Search for medicines Search
 European Medicines Agency1 month ago New Drugs Approved by the EU 2015 | Comparison of New Drug Approval Speed of the Europe and Amerian  CPhI.cn1 week ago

Janssen and Johnson & Johnson to Provide Webcast Presentation on the Janssen Oncology Hematologic Malignancy Portfolio

From the Wires Emphasis on Clinical Data Presented on DARZALEX (daratumumab) and IMBRUVICA® (ibrutinib) at the American Society of Hematology (ASH) in December 2015 Jan. 15, 2016 10:22 AM NEW BRUNSWICK, N.J. , Jan.15, 2016 /PRNewswire/ ...
 Sys-Con India3 weeks ago Investing In Johnson & Johnson's Pharmaceutical Collaborations Can Provide Dramatic Returns  Seeking Alpha1 month ago Janssen and Johnson Johnson to Provide Webcast Presentation on the Janssen Oncology Hematologic Malignancy Portfolio  Pharma Focus Asia3 weeks ago Janssen Research & Development And Johnson & Johnson To Provide Webcast Presentation On The Janssen Oncology Hematologic Malignancy Portfolio  BioSpace3 weeks ago
[x]  
Huffington Post

Follow-up results of looking at treatment with ibrutinib on CLL patient survival and adverse events

Description: Jacqueline Barrientos, MD, discusses a recent follow-up study looking at CLL patient outcomes following treatment with ibrutinib, including populations that had no post-trial access to ibrutinib, or those who moved to a comparator. The ...
 Oncology Tube1 month ago New Cancer Drug Ibrutinib Outperforms Chemo For Some Patients  Huffington Post2 months ago Hitting a CLL Treatment Home Run  Oncology Tube1 month ago
European Pharmaceutical Review

IMBRUVICA® (ibrutinib) RESONATE-2 Data Show Significant Improvements in Progression-Free and Overall Survival Versus Chlorambucil in Previously Untreated Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

These Phase 3 data were presented at The American Society of Hematology (ASH) Annual Meeting and simultaneously published in The New England Journal of Medicine TORONTO, Dec. 8, 2015 /CNW/ - Data from the Phase 3 RESONATE TM -2 (PCYC-1115) trial ...
 Bloomberg2 months ago Ibrutinib shown to be superior to chlorambucil in trial  European Pharmaceutical Review2 months ago Janssen Research & Development Release: Ibrutinib (IMBRUVICA) Significantly Improved Progression-Free And Overall Survival Versus Chlorambucil In Patients With Treatment-Naive Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma  BioSpace2 months ago Ibrutinib Monotherapy Superior to Chlorambucil in Treatment-nave Older Patients With CLL/SLL  Cancer Therapy Advisor2 months ago
[x]  

Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia

Chronic lymphocytic leukemia (CLL) is the most common leukemia among adults in Western countries; it affects primarily older persons, with a median age at diagnosis of 72 years. 1,2 Chlorambucil has been a standard first-line therapy in CLL, ...
 New England Journal of Medicine2 months ago Best Leukemia Abstracts from ASH 2015  Oncology Times3 weeks ago
LymphomaNewsToday.com

PHARMACYCLICS : Ibrutinib (IMBRUVICA®) Combination Data Show Promise in Patients with Relapsed/Refractory Multiple Myeloma

ba940ac0-67c0-4483-acd4-0eff0f0ec2a3.pdf PRESS RELEASE Ibrutinib (IMBRUVICA ® ) Combination Data Show Promise in Patients with Relapsed/Refractory
 4 Traders1 month ago Ibrutinib, rituximab appear safe, effective for treatment-naive follicular lymphoma  Orthopedics Today1 month ago Treatment-Naive Follicular Lymphoma Patients Respond Well to Ibrutinib Combo Therapy  LymphomaNewsToday.com1 month ago IMBRUVICA® (ibrutinib) Phase 2 RESONATE-17 Data Show Robust Clinical Activity and Promising Survival Outcomes in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia with del 17p  Wall Street Select2 months ago
[x]  
ASH Clinical News

RESONATE-2: Ibrutinib Safe, Effective in Older Patients with CLL/SLL

Chlorambucil is considered a standard therapy for older patients with chronic lymphocytic leukemia (CLL) but, according to results from the RESONATE-2 trial presented at the 2015 ASH Annual Meeting, ibrutinib could take over as standard, first-line ...
 ASH Clinical News3 weeks ago Study shows ibrutinib superior to traditional chemotherapy in untreated chronic leukemia patients  Health Canal1 month ago First-Line Ibrutinib Improves Survival in Frail CLL Patients  MyInforms2 months ago ASH: First-line ibrutinib beats standard chemo for CLL/SLL in older patients  PM 3602 months ago
[x]  
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
1.
2.
3.
4.
5.
6.
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts

Get

Realtime News

on your Webpage

Add Widget >Get your members hooked!
Related Queries - Ibrutinib
    
Alerts
Get updated on latest news & your favorite topics right in your inbox!
 
More     Less